New drug trial aims to stop genetic Alzheimer's before it starts
NCT ID NCT06384573
Summary
This study is testing the drug lecanemab in people who have a genetic form of Alzheimer's disease and have already been in a related long-term trial. The main goal is to see if aggressively removing amyloid plaque from the brain years before symptoms typically appear can significantly delay or even prevent the onset of dementia. Researchers will closely monitor 40 participants to understand the long-term effects of this treatment approach.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALZHEIMER'S DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Indiana University School of Medicine
Indianapolis, Indiana, 46202, United States
-
Neuroscience Research Australia
Randwick, New South Wales, 2031, Australia
-
The National Hospital for Neurology and Neurosurgery
London, Greater London, WC1B 3BG, United Kingdom
-
University of Alabama in Birmingham
Birmingham, Alabama, 35294, United States
-
University of Washington
Seattle, Washington, 98195, United States
-
Washington University in St. Louis
St Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.